Introduction: In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory
We successfully develop a two-in-one approach to generate non-viral genome specific targeted CAR T cells through CRISPRCas9. In the adoptive therapy for relapsedrefractory aggressive B-cell non-Hodgki
Chimeric antigen receptor (CAR) T cells targeting CD19 are highly effective against B-lineage malignancies. However, about half of patients either fail to achieve complete remission (in the case of ly
Global CAR-T Therapy comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential ma
